Six out of sixteen cell lines: colorectal carcinoma cell line SW837, pancreatic cancer cell line Panc 10.05 and lung cancer cell lines NCI-H1437, NCI-H358, A549 and NCI-H2030 showed robust knockdown of KRAS mRNA but with moderate IC50 (>600 nM, <2 μM) and six out of sixteen cell lines: colorectal carcinoma cell lines SW620 and HT-29, pancreatic cancer cell line BxPC3 and lung cancer cell lines Calu-6, A427 and LK2 showed poor response to treatment with AZD4785, with little to no KRAS mRNA knockdown and high IC50 (>2 μM) (Figure 1A and Supplementary Figure S2). This evidence concerns the gene KRAS and lung carcinoma.